乙酰化调控机制在血管衰老中的研究进展

doi:10.3969/j.issn.1003-9198.2026.01.015

摘要/Abstract

摘要： 血管衰老与高血压、动脉粥样硬化等心血管疾病的发生发展密切相关,其机制复杂,涉及多种分子通路。乙酰化修饰通过影响蛋白质稳定性、酶活性和亚细胞定位,广泛参与脂质合成、DNA损伤修复、糖酵解和细胞周期进展等多种生物学活动。本文系统综述了乙酰化修饰在血管衰老中的作用机制,包括组蛋白和非组蛋白乙酰化调控功能,并对相关潜在治疗靶点进行展望,以期为血管衰老相关疾病的防治提供新思路。

关键词: 血管衰老, 乙酰化调控, 组蛋白乙酰化, 非组蛋白乙酰化

Abstract: Vascular aging is closely associated with the onset and progression of cardiovascular diseases such as hypertension and atherosclerosis.The underlying mechanisms are complex and involve multiple molecular pathways. Acetylation modification regulates multiple biological processes including lipid synthesis, DNA damage repair, glycolysis, and cell cycle progression by modulating protein stability, enzyme activity, and subcellular localization. This review summarizes the acetylation regulatory mechanisms in vascular aging, including histone acetylation regulation and non-histone acetylation regulation, and discusses potential therapeutic targets to provide new ideas for the prevention and treatment of vascular aging-related diseases.

Key words: vascular senescence, acetylation regulation, histone acetylation, non-histone acetylation

中图分类号:

R 543

李红, 李树斌, 邬倩, 殷亚宁, 孙于欣, 格日乐其其格, 李卫红, 张士琦, 邬真力. 乙酰化调控机制在血管衰老中的研究进展[J]. 实用老年医学, 2026, 40(1): 72-77.

LI Hong, LI Shubin, WU Qian, YIN Yaning, SUN Yuxin, Gerileqiqige, LI Weihong, ZHANG Shiqi, WU Zhenli. Research progress on the regulatory mechanism of acetylation in vascular aging[J]. Practical Geriatrics, 2026, 40(1): 72-77.

参考文献

[1] GUO J, HUANG X, DOU L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments[J]. Signal Transduct Target Ther, 2022, 7(1): 391.
[2] SHVEDUNOVA M, AKHTAR A. Modulation of cellular processes by histone and non-histone protein acetylation[J]. Nat Rev Mol Cell Biol, 2022, 23(5): 329-349.
[3] ALI I, CONRAD R J, VERDIN E, et al. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics[J]. Chem Rev, 2018, 118(3): 1216-1252.
[4] ZHONG Q, XIAO X, QIU Y, et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications[J]. Med Comm: 2020, 2023, 4(3): e261.
[5] CAI Y, SONG W, LI J, et al. The landscape of aging[J].Sci China Life Sci, 2022, 65(12):2354-2454.
[6] 王凯, 范小璇, 王欢, 等. 血管老化发生机制及相关靶点的研究进展[J]. 实用老年医学, 2021, 35(7): 750-753.
[7] DING Y N, TANG X, CHEN H Z, et al. Epigenetic regulation of vascular aging and age-related vascular diseases[J]. Adv Exp Med Biol, 2018, 1086: 55-75.
[8] TARANTINI S, VALCARCEL-ARES N M, YABLUCHANSKIY A, et al. Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice[J]. Aging Cell, 2018, 17(2): e12731.
[9] GORGOULIS V, ADAMS P D, ALIMONTI A, et al. Cellular senescence: defining a path forward[J]. Cell, 2019, 179(4): 813-827.
[10] VERMOT A, PETIT-HÄRTLEIN I, SMITH S M E, et al. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology[J]. Antioxidants, 2021, 10(6): 890.
[11] KAMTCHUM-TATUENE J, SABA L, HELDNER M R, et al. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression[J]. Circ Res, 2022, 131(2): e22-e33.
[12] 陈映泉, 钟勇. 心血管老化的机制、标志物和治疗[J]. 实用老年医学, 2024, 38(3): 299-303.
[13] DING Q, SHAO C, ROSE P, et al. Epigenetics and vascular senescence-potential new therapeutic targets?[J].Front Pharmacol, 2020, 11: 535395.
[14] BURDUSEL D, DOEPPNER T R, SURUGIU R, et al. The intersection of epigenetics and senolytics in mechanisms of aging and therapeutic approaches[J]. Biomolecules, 2024, 15(1): 18.
[15] LIU X, JIANG D, HUANG W, et al. Sirtuin 6 attenuates angiotensin II-induced vascular adventitial aging in rat aortae by suppressing the NF-κB pathway[J]. Hypertens Res, 2021, 44(7): 770-780.
[16] ECKSCHLAGER T, PLCH J, STIBOROVA M, et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci, 2017, 18(7): 1414.
[17] GUJRAL P, MAHAJAN V, LISSAMAN A C, et al. Histone acetylation and the role of histone deacetylases in normal cyclic endometrium[J]. Reprod Biol Endocrinol, 2020, 18(1): 84.
[18] PARK S Y, KIM J S. A short guide to histone deacetylases including recent progress on class II enzymes[J]. Exp Mol Med, 2020, 52(2): 204-212.
[19] RAJMAN L, CHWALEK K, SINCLAIR D A. Therapeutic potential of NAD-boosting molecules: the in vivo evidence[J]. Cell Metab, 2018, 27(3): 529-547.
[20] ZHA S, LI Z, CAO Q, et al. PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD⁺ levels and increasing SIRT1 activity[J]. Stem Cell Res Ther, 2018, 9(1): 224.
[21] CAMACHO-PEREIRA J, TARRAGÓ M G, CHINI C C S, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism[J]. Cell Metab, 2016, 23(6): 1127-1139.
[22] LI D, LI W, LIAO X, et al. NAD⁺-dependent Sirt6 is a key regulator involved in telomere shortening of in vitro-cultured preimplantation embryos[J]. Commun Biol, 2025, 8(1): 1275.
[23] LIN Z, DING Q, LI X, et al. Targeting epigenetic mechanisms in vascular aging[J]. Front Cardiovasc Med, 2022, 8: 806988.
[24] DING Y N, WANG T T, LV S J, et al. SIRT6 is an epigenetic repressor of thoracic aortic aneurysms via inhibiting inflammation and senescence[J]. Signal Transduct Target Ther, 2023, 8(1): 255.
[25] YANG Z, HUANG Y, ZHU L, et al. SIRT6 promotes angiogenesis and hemorrhage of carotid plaque via regulating HIF-1α and reactive oxygen species[J]. Cell Death Dis, 2021, 12(1): 77.
[26] XIONG J, MA F, DING N, et al. miR-195-3p alleviates homocysteine-mediated atherosclerosis by targeting IL-31 through its epigenetics modifications[J]. Aging Cell, 2021, 20(10): e13485.
[27] NGUBO M, CHEN Z, MCDONALD D, et al. Progeria-based vascular model identifies networks associated with cardiovascular aging and disease[J]. Aging Cell, 2024, 23(7): e14150.
[28] LEE G H, HOANG T H, JUNG E S, et al. Anthocyanins attenuate endothelial dysfunction through regulation of uncoupling of nitric oxide synthase in aged rats[J]. Aging Cell, 2020, 19(12): e13279.
[29] DI TOMO P, ALESSIO N, FALONE S, et al. Endothelial cells from umbilical cord of women affected by gestational diabetes: a suitable in vitro model to study mechanisms of early vascular senescence in diabetes[J]. FASEB J, 2021, 35(6): e21662.
[30] FURUKAWA A, TADA-OIKAWA S, KAWANISHI S, et al. H₂O₂ accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion[J]. Cell Physiol Biochem, 2007, 20(1/2/3/4): 45-54.
[31] YAN P, LI Z, XIONG J, et al. LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activity[J]. Cell Rep, 2021, 37(8): 110038.
[32] CHEN Y X, YANG H, WANG D S, et al. Gastrodin alleviates mitochondrial dysfunction by regulating SIRT3-mediated TFAM acetylation in vascular dementia[J]. Phytomedicine, 2024, 128: 155369.
[33] WU Y, TANG L, HUANG H, et al. Phosphoglycerate dehydrogenase activates PKM2 to phosphorylate histone H3T11 and attenuate cellular senescence[J]. Nat Commun, 2023, 14(1): 1323.
[34] HU J, LEISEGANG M S, LOOSO M, et al. Disrupted binding of cystathionine γ-lyase to p53 promotes endothelial senescence[J]. Circ Res, 2023, 133(10): 842-857.
[35] CAO X, WU Y, HONG H, et al. Sirtuin 3 dependent and independent effects of NAD⁺ to suppress vascular inflammation and improve endothelial function in mice[J]. Antioxidants, 2022, 11(4): 706.
[36] PEI Z, DONG M, MENG X, et al. Effects of nicotinamide adenine dinucleotide on older patients with heart failure[J]. Rev Cardiovasc Med, 2024, 25(8): 297.
[37] REN S C, CHEN X, GONG H, et al. SIRT6 in vascular diseases, from bench to bedside[J]. Aging Dis, 2022, 13(4): 1015-1029.
[38] ZHONG W, YANG Y, WANG Y. Liraglutide attenuates high glucose-induced endothelial cell senescence and dysfunction via SIRT1-mediated deacetylation of p53/p65[J]. Tissue Cell, 2025, 95: 102882.